MAVENCLAD 10 mg, tablet tablet
Active ingredients: Cladribine
Commercialized according to BDPMDispensing in France: Prescription only
Tablettabletorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- MAVENCLAD 10 mg, comprimé
- Pharmaceutical form
- comprimé
- Route of administration
- orale
- Presentation description
- plaquette(s) aluminium de 1 comprimé(s)
- Marketing authorisation holder
- MERCK SERONO EUROPE (ROYAUME-UNI)
- Reimbursement according to BDPM
- 15 %
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 19 Mar 2021
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
65820786CIP73011179CIP133400930111796Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| CLADRIBINEcomprimé | 10 mg · un comprimé | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Other packages of this medicine
The same medicine in another pack size, according to BDPM.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.